Type 1 diabetes in children — MCQs

10 questions

A 6-month-old baby presents with failure to thrive, chronic diarrhea, and recurrent respiratory infections. Sweat chloride test is 70 mmol/L (normal <40). What is the most likely diagnosis?

A 16-year-old girl with type 1 diabetes for 10 years attends for transition planning to adult services. Her HbA1c has been consistently between 65-72 mmol/mol over the past 2 years. Annual screening shows persistent microalbuminuria (ACR 4.8 mg/mmol) and background diabetic retinopathy with scattered microaneurysms bilaterally. She is on appropriate therapy including an ACE inhibitor. She asks about her long-term prognosis. What is the most appropriate counselling regarding her microvascular complications?

A 4-year-old boy with newly diagnosed generalized epilepsy is being commenced on sodium valproate. His mother asks about potential side effects. Which of the following monitoring investigations should be performed before starting sodium valproate and at regular intervals during treatment?

A 13-year-old boy with type 1 diabetes for 7 years presents with intermittent episodes of abdominal bloating, early satiety, nausea, and vomiting, particularly after meals. He reports that vomiting sometimes contains food eaten several hours earlier. His HbA1c is 82 mmol/mol. On examination, he has mild epigastric tenderness and a succussion splash. Screening for coeliac disease is negative. What is the most likely diagnosis?

A 10-year-old girl with type 1 diabetes for 5 years uses insulin glargine 18 units once daily at bedtime and insulin aspart before meals. She participates in competitive gymnastics training 5 evenings per week from 5-7pm. Her mother reports that she frequently becomes hypoglycaemic during and after training sessions despite eating extra snacks. Pre-dinner glucose is usually 8-10 mmol/L. What is the most appropriate modification to her insulin regimen?

A 7-year-old boy with newly diagnosed focal epilepsy is being considered for anti-epileptic drug therapy. His seizures consist of focal motor seizures affecting his right arm with preserved awareness, occurring 2-3 times per week. MRI brain shows a small left frontal cortical dysplasia. His parents are concerned about side effects of medication. Which of the following statements regarding the decision to commence anti-epileptic drug treatment is most accurate?

A 15-year-old boy with type 1 diabetes for 9 years attends clinic with his parents. Over the past year, his HbA1c has deteriorated from 58 mmol/mol to 85 mmol/mol. He admits to frequently missing insulin doses and not checking his blood glucose. He expresses frustration about being 'different' from his peers and wanting to be 'normal'. His parents report frequent arguments at home about diabetes management. What is the most appropriate initial approach to address this situation?

A 5-year-old girl presents to the emergency department with a 20-minute generalized tonic-clonic seizure that has not responded to two doses of buccal midazolam given by paramedics. Intravenous access is established. Blood glucose is 5.2 mmol/L. What is the most appropriate next immediate management?

Which of the following is the primary mechanism by which the ketogenic diet exerts its anti-epileptic effect in children with drug-resistant epilepsy?

Q10

A 9-year-old boy with type 1 diabetes for 4 years uses a basal-bolus insulin regimen. His parents report that his morning pre-breakfast blood glucose readings are consistently high (12-15 mmol/L), despite having good control during the day. His bedtime readings are usually 6-8 mmol/L. A continuous glucose monitor shows that his glucose drops to 3.2 mmol/L at 2am then rises sharply to 14 mmol/L by 7am. What is the most appropriate adjustment to his insulin regimen?

Type 1 diabetes in children UK Medical PG Practice Questions and MCQs

Question 1: A 6-month-old baby presents with failure to thrive, chronic diarrhea, and recurrent respiratory infections. Sweat chloride test is 70 mmol/L (normal <40). What is the most likely diagnosis?

A. Celiac disease
B. Cystic fibrosis (Correct Answer)
C. Immunodeficiency
D. Inflammatory bowel disease
E. Lactose intolerance

Explanation: ***Cystic fibrosis***- The constellation of **failure to thrive**, chronic **malabsorptive diarrhea** (due to **pancreatic insufficiency**), and recurrent **respiratory infections** (due to thick mucus) is classic for **Cystic fibrosis**.- A sweat chloride level of 70 mmol/L is diagnostic for **Cystic fibrosis** in an infant (cut-off is typically >60 mmol/L), confirming the defect in the **CFTR channel**.*Celiac disease*- While a cause of failure to thrive and chronic diarrhea, symptoms typically manifest after the introduction of **gluten** (usually after 6 months of age) and often involve abdominal distension.- It does not cause recurrent respiratory infections as a primary feature, nor is it associated with an elevated **sweat chloride** level.*Immunodeficiency*- This could explain **recurrent respiratory infections** and failure to thrive, but it typically does not cause the specific syndrome of chronic steatorrhea due to **pancreatic insufficiency**.- Immunodeficiency conditions do not result in an abnormally high **sweat chloride** test result.*Inflammatory bowel disease*- IBD rarely presents in early infancy (6 months) and usually causes features like **bloody diarrhea** and **abdominal pain** rather than the typical **steatorrhea** associated with pancreatic insufficiency.- IBD is not associated with an elevated **sweat chloride** test or recurrent sino-pulmonary infections driven by mucus accumulation.*Lactose intolerance*- This causes osmotic diarrhea and potentially failure to thrive, but the symptoms are strictly gastrointestinal and often improve when **lactose** is removed from the diet.- It does not explain the hallmark triad of pulmonary disease, malabsorption, and the pathognomonic **elevated sweat chloride**.

Question 2: A 16-year-old girl with type 1 diabetes for 10 years attends for transition planning to adult services. Her HbA1c has been consistently between 65-72 mmol/mol over the past 2 years. Annual screening shows persistent microalbuminuria (ACR 4.8 mg/mmol) and background diabetic retinopathy with scattered microaneurysms bilaterally. She is on appropriate therapy including an ACE inhibitor. She asks about her long-term prognosis. What is the most appropriate counselling regarding her microvascular complications?

A. Microalbuminuria at this stage is irreversible regardless of subsequent glycaemic control
B. With current control, progression to end-stage renal disease is inevitable within 10 years
C. Optimizing glycaemic control now can still slow progression even with established complications (Correct Answer)
D. Background retinopathy always progresses to proliferative retinopathy requiring laser therapy
E. Presence of two microvascular complications indicates imminent need for renal transplantation

Explanation: ***Optimizing glycaemic control now can still slow progression even with established complications*** - The **Diabetes Control and Complications Trial (DCCT)** and EDIC studies confirm that improving glycaemic control reduces the risk of **microvascular progression** even after complications like **microalbuminuria** or **background retinopathy** appear. - Achieving a target **HbA1c <48 mmol/mol** is critical during transition to prevent the worsening of damage through the mechanism of **metabolic memory**. *Microalbuminuria at this stage is irreversible regardless of subsequent glycaemic control* - **Microalbuminuria** (ACR 3–30 mg/mmol) is potentially **reversible** or can be stabilized with intensive glycaemic control and **ACE inhibitor** therapy. - Progression to **macroalbuminuria** is common if control remains poor, but early intervention often leads to **regression** to normoalbuminuria. *With current control, progression to end-stage renal disease is inevitable within 10 years* - While an HbA1c of 65-72 mmol/mol increases risk, **End-Stage Renal Disease (ESRD)** typically takes decades to develop, and many patients with early nephropathy remain **stable for years**. - Labelling ESRD as **inevitable** is clinically inaccurate and discouraged in transition counselling as it ignores the impact of **blood pressure** and glycaemic management. *Background retinopathy always progresses to proliferative retinopathy requiring laser therapy* - **Background retinopathy** (microaneurysms) may remain stable for long periods or even **regress** if glycaemic control and **blood pressure** are well-managed. - Progression to **proliferative diabetic retinopathy (PDR)** is not a certainty and depends heavily on the duration of **hyperglycaemia**. *Presence of two microvascular complications indicates imminent need for renal transplantation* - The presence of multiple complications indicates a **high-risk profile** requiring intensive multidisciplinary care, but does not suggest **acute organ failure**. - **Renal transplantation** is only considered for stage 5 **chronic kidney disease**, whereas this patient currently has early-stage **diabetic nephropathy**.

Question 3: A 4-year-old boy with newly diagnosed generalized epilepsy is being commenced on sodium valproate. His mother asks about potential side effects. Which of the following monitoring investigations should be performed before starting sodium valproate and at regular intervals during treatment?

A. Full blood count, renal function, and thyroid function tests
B. Liver function tests, full blood count, and serum ammonia (Correct Answer)
C. Electrocardiogram, liver function tests, and lipid profile
D. Full blood count, vitamin D levels, and bone density scan
E. Renal function, serum drug levels, and electroencephalogram

Explanation: ***Liver function tests, full blood count, and serum ammonia***- Sodium valproate carries a risk of idiosyncratic **hepatotoxicity**, making baseline and regular **Liver Function Tests (LFTs)** essential, especially during the first 6 months of therapy.- **Full blood count (FBC)** is required to monitor for **thrombocytopenia** and other blood dyscrasias, while **serum ammonia** helps detect valproate-induced **hyperammonemia** which can present as lethargy or confusion.*Full blood count, renal function, and thyroid function tests*- While FBC is necessary, valproate is not primarily excreted by the kidneys and does not typically cause **renal impairment** requiring routine monitoring.- **Thyroid function tests** are not standard for valproate; they are more relevant for medications like **lithium** or **amiodarone**.*Electrocardiogram, liver function tests, and lipid profile*- **ECG monitoring** is not routinely required for valproate, unlike drugs like **tricyclic antidepressants** or certain antipsychotics that affect the **QT interval**.- Although valproate can cause **weight gain**, a routine **lipid profile** is not a primary safety monitoring requirement compared to LFTs and hematology.*Full blood count, vitamin D levels, and bone density scan*- Long-term anticonvulsant use is linked to **reduced bone mineral density**, but **DEXA scans** are not part of the standard pre-treatment or early routine monitoring battery.- Monitoring **vitamin D** may be considered long-term, but it is less critical than monitoring for acute **liver failure** or **bone marrow suppression**.*Renal function, serum drug levels, and electroencephalogram*- Unlike phenytoin or carbamazepine, there is a poor correlation between **serum drug levels** and the therapeutic effect or toxicity of valproate, so routine monitoring is not indicated.- An **EEG** is used for diagnosis and classification of epilepsy rather than as a routine investigation to monitor for medication **side effects**.

Question 4: A 13-year-old boy with type 1 diabetes for 7 years presents with intermittent episodes of abdominal bloating, early satiety, nausea, and vomiting, particularly after meals. He reports that vomiting sometimes contains food eaten several hours earlier. His HbA1c is 82 mmol/mol. On examination, he has mild epigastric tenderness and a succussion splash. Screening for coeliac disease is negative. What is the most likely diagnosis?

A. Diabetic ketoacidosis with gastric stasis
B. Gastroparesis secondary to diabetic autonomic neuropathy (Correct Answer)
C. Superior mesenteric artery syndrome
D. Helicobacter pylori-associated gastritis
E. Coeliac disease with false-negative serology

Explanation: ***Gastroparesis secondary to diabetic autonomic neuropathy*** - This condition is a classic complication of long-standing **Type 1 Diabetes** with poor glycemic control, leading to delayed gastric emptying due to **vagal nerve damage**.- Symptoms like **early satiety**, vomiting of food consumed hours prior, and a positive **succussion splash** indicating retained gastric contents are pathognomonic.*Diabetic ketoacidosis with gastric stasis*- While **DKA** can cause acute gastroparesis, it typically presents with acute-onset abdominal pain, **uncompensated metabolic acidosis**, and ketosis, which are not described here.- The history of intermittent postprandial symptoms over time is more indicative of a **chronic autonomic neuropathy** than an acute metabolic emergency.*Superior mesenteric artery syndrome*- This occurs when the **duodenum** is compressed between the SMA and the aorta, usually following **rapid weight loss**.- Although it presents with postprandial vomiting, it is less common in this clinical context and would not be primary suspected over **diabetic neuropathy** in a long-standing diabetic.*Helicobacter pylori-associated gastritis*- **H. pylori** commonly causes chronic epigastric pain and dyspepsia, but it does not typically lead to mechanical or functional **gastric outlet obstruction**.- The presence of a **succussion splash** strongly suggests a motility or obstructive disorder rather than simple mucosal inflammation.*Coeliac disease with false-negative serology*- While **Coeliac disease** is frequently associated with Type 1 Diabetes, it usually presents with diarrhea, malabsorption, or growth failure rather than **gastric stasis**.- Serology was negative, and the specific finding of a **succussion splash** is not a feature of Coeliac disease.

Question 5: A 10-year-old girl with type 1 diabetes for 5 years uses insulin glargine 18 units once daily at bedtime and insulin aspart before meals. She participates in competitive gymnastics training 5 evenings per week from 5-7pm. Her mother reports that she frequently becomes hypoglycaemic during and after training sessions despite eating extra snacks. Pre-dinner glucose is usually 8-10 mmol/L. What is the most appropriate modification to her insulin regimen?

A. Increase the pre-lunch insulin aspart dose to provide better afternoon glucose control
B. Switch insulin glargine from bedtime to morning administration
C. Add metformin to reduce insulin requirements
D. Reduce the pre-lunch insulin aspart dose by 30-50% on training days (Correct Answer)
E. Split insulin glargine to twice daily administration with reduced total daily dose

Explanation: ***Reduce the pre-lunch insulin aspart dose by 30-50% on training days***- Exercise increases **insulin sensitivity** and glucose uptake by muscles, requiring less insulin to maintain euglycemia, especially during the period of physical activity.- Rapid-acting insulin administered before lunch, such as **insulin aspart**, will still have significant activity during late afternoon gymnastics, making a dose reduction crucial to prevent **exercise-induced hypoglycemia**.*Increase the pre-lunch insulin aspart dose to provide better afternoon glucose control*- Increasing the dose of **pre-lunch aspart** would heighten the risk of **hypoglycemia** during the strenuous evening gymnastics, as more insulin would be active during this period.- The reported pre-dinner glucose levels of 8-10 mmol/L are not high enough to justify an increase that would likely lead to dangerous hypoglycemia during exercise.*Switch insulin glargine from bedtime to morning administration*- Changing the timing of **basal insulin** like glargine does not directly address the peak action of **bolus insulin** (aspart) which is responsible for the hypoglycemia during late afternoon activity.- This modification could also disrupt the overall **basal insulin coverage**, potentially leading to suboptimal glycemic control at other times, including nocturnal hyperglycemia.*Add metformin to reduce insulin requirements*- **Metformin** is primarily used in **Type 2 Diabetes** or **Type 1 Diabetes** with significant insulin resistance; it is not indicated for managing acute exercise-induced hypoglycemia in a 10-year-old with uncomplicated T1DM.- Its mechanism of action doesn't directly solve the issue of excess rapid-acting insulin activity during exercise, which is the root cause of the patient's hypoglycemia.*Split insulin glargine to twice daily administration with reduced total daily dose*- While splitting the **basal insulin** dose can sometimes improve glycemic stability, it is not the most targeted intervention for hypoglycemia specifically caused by **exercise-induced increased insulin sensitivity** interacting with mealtime bolus insulin.- Reducing the total daily basal dose might compromise overall glycemic control and lead to **hyperglycemia** on non-training days or at other times.

Question 6: A 7-year-old boy with newly diagnosed focal epilepsy is being considered for anti-epileptic drug therapy. His seizures consist of focal motor seizures affecting his right arm with preserved awareness, occurring 2-3 times per week. MRI brain shows a small left frontal cortical dysplasia. His parents are concerned about side effects of medication. Which of the following statements regarding the decision to commence anti-epileptic drug treatment is most accurate?

A. Focal seizures with preserved awareness do not require anti-epileptic treatment
B. Anti-epileptic drugs should be started immediately after a single unprovoked seizure to prevent recurrence
C. The presence of a structural brain lesion increases the risk of seizure recurrence and supports starting treatment (Correct Answer)
D. Anti-epileptic drugs are contraindicated in children under 10 years due to neurodevelopmental concerns
E. Treatment should be delayed until seizures occur daily to confirm the diagnosis

Explanation: ***The presence of a structural brain lesion increases the risk of seizure recurrence and supports starting treatment*** - The identification of a **structural brain lesion**, specifically **cortical dysplasia** on MRI, significantly increases the risk of **seizure recurrence** and qualifies for a diagnosis of epilepsy, even after a single unprovoked seizure. - With seizures occurring 2-3 times per week and a high risk of recurrence due to the underlying pathology, commencing **anti-epileptic drug (AED)** therapy is medically appropriate to improve seizure control and prevent further complications. *Focal seizures with preserved awareness do not require anti-epileptic treatment* - While awareness is preserved, recurrent **focal motor seizures** (2-3 times per week) can significantly disrupt a child's life and carry a risk of **secondary generalization**. - The decision to initiate treatment is based on seizure frequency, impact on daily activities, and the presence of an underlying structural cause, rather than solely on the preservation of awareness. *Anti-epileptic drugs should be started immediately after a single unprovoked seizure to prevent recurrence* - Routine immediate initiation of **AEDs** after a single unprovoked seizure is not typically recommended unless there are specific **high-risk factors** for recurrence, such as an abnormal EEG or structural brain lesion. - In many cases, a single unprovoked seizure may not lead to further events, and the decision to treat involves carefully weighing the risk of recurrence against potential medication side effects. *Anti-epileptic drugs are contraindicated in children under 10 years due to neurodevelopmental concerns* - **AEDs** are commonly and safely prescribed for children of all ages, including those under 10, when indicated for **epilepsy management**. - Uncontrolled or frequent seizures themselves pose a substantial risk to a child's **neurodevelopment** and cognitive function, making appropriate treatment crucial despite potential side effects, which are managed by careful drug selection and monitoring. *Treatment should be delayed until seizures occur daily to confirm the diagnosis* - Delaying treatment until **daily seizures** occur is not recommended as it unnecessarily increases the risk of **status epilepticus**, injuries, and potential **long-term neurological morbidity**. - The diagnosis of epilepsy is sufficiently confirmed by recurrent seizures (2-3 times per week) in the presence of a clear **focal cortical dysplasia**, warranting earlier intervention.

Question 7: A 15-year-old boy with type 1 diabetes for 9 years attends clinic with his parents. Over the past year, his HbA1c has deteriorated from 58 mmol/mol to 85 mmol/mol. He admits to frequently missing insulin doses and not checking his blood glucose. He expresses frustration about being 'different' from his peers and wanting to be 'normal'. His parents report frequent arguments at home about diabetes management. What is the most appropriate initial approach to address this situation?

A. Arrange immediate referral to child and adolescent mental health services
B. Initiate continuous glucose monitoring to improve awareness of glucose levels
C. Explore the patient's perspective and concerns using motivational interviewing techniques (Correct Answer)
D. Inform the parents that they need to resume full responsibility for diabetes management
E. Switch to insulin pump therapy to simplify the treatment regimen

Explanation: ***Explore the patient's perspective and concerns using motivational interviewing techniques*** - The significant deterioration in **HbA1c** and poor adherence in an adolescent strongly suggest underlying **psychosocial factors**, such as the desire for autonomy and fitting in with peers. - **Motivational interviewing** is the most appropriate initial step to explore his feelings of being 'different', validate his frustrations, and collaboratively identify his own motivations for better self-management. *Arrange immediate referral to child and adolescent mental health services* - While mental health is a factor in adherence, his stated frustrations about being 'different' are common **adolescent struggles** with chronic illness, not immediate indicators for specialist **CAMHS referral** for a diagnosed disorder. - A referral might be considered if initial interventions fail or if symptoms of a severe mental health condition (e.g., clinical depression, anxiety disorder) are clearly present. *Initiate continuous glucose monitoring to improve awareness of glucose levels* - The patient's issue is not a lack of awareness of his glucose levels, but rather a lack of **motivation** and engagement with his diabetes management. - Introducing **continuous glucose monitoring (CGM)** without addressing the underlying emotional barriers may further burden him and reinforce his feeling of being 'different', potentially worsening adherence. *Inform the parents that they need to resume full responsibility for diabetes management* - Removing autonomy from a 15-year-old can exacerbate **family conflict** and lead to increased rebellion against diabetes management, as adolescents seek greater independence. - The goal is to support the adolescent in gradually assuming more responsibility, not to revert to full parental control, which can be counterproductive in this age group. *Switch to insulin pump therapy to simplify the treatment regimen* - **Insulin pump therapy** requires significant patient engagement, training, and careful self-management; it is not a 'simpler' solution for a patient who is already non-adherent. - Introducing a pump to a patient lacking motivation could increase the risk of serious complications like **diabetic ketoacidosis (DKA)** if not managed properly, as it does not address the emotional barriers.

Question 8: A 5-year-old girl presents to the emergency department with a 20-minute generalized tonic-clonic seizure that has not responded to two doses of buccal midazolam given by paramedics. Intravenous access is established. Blood glucose is 5.2 mmol/L. What is the most appropriate next immediate management?

A. Intravenous lorazepam 0.1 mg/kg (Correct Answer)
B. Rectal paraldehyde 0.4 ml/kg
C. Intravenous phenytoin 20 mg/kg infusion
D. Intramuscular phenobarbital 20 mg/kg
E. Intravenous levetiracetam 40 mg/kg

Explanation: ***Intravenous lorazepam 0.1 mg/kg*** - The child is experiencing **status epilepticus** as the seizure has lasted 20 minutes and buccal midazolam has failed. - With **IV access** established, **intravenous lorazepam** is the recommended **first-line benzodiazepine** for terminating acute seizures in the hospital setting due to its rapid action and sustained effect.*Rectal paraldehyde 0.4 ml/kg* - **Rectal paraldehyde** is a historical alternative, primarily considered only when **IV access cannot be obtained**, which is not the case here. - Its use has been largely superseded by safer and more effective **IV benzodiazepines** in modern emergency management protocols.*Intravenous phenytoin 20 mg/kg infusion* - **Phenytoin** is typically a **second or third-line agent** for **refractory status epilepticus**, used when benzodiazepines have failed. - The immediate next step after initial benzodiazepine failure and IV access establishment is another **IV benzodiazepine**, not a loading dose of phenytoin.*Intramuscular phenobarbital 20 mg/kg* - While **phenobarbital** is an antiepileptic, it is typically administered **intravenously** for status epilepticus, not intramuscularly, for rapid onset of action. - It is also generally reserved as a **third-line agent** for refractory cases, not as the immediate next step after initial benzodiazepine failure.*Intravenous levetiracetam 40 mg/kg* - **Levetiracetam** is recognized as a **third-line agent** for **refractory status epilepticus**, used after benzodiazepines and other second-line agents (like phenytoin) have failed. - The current situation requires immediate termination with a **first-line IV benzodiazepine** following initial treatment failure and established IV access.

Question 9: Which of the following is the primary mechanism by which the ketogenic diet exerts its anti-epileptic effect in children with drug-resistant epilepsy?

A. Reduction in neuronal excitability through GABA receptor upregulation
B. Inhibition of voltage-gated sodium channels in neuronal membranes
C. Metabolic shift producing ketone bodies that stabilize neuronal membranes and alter neurotransmitter levels (Correct Answer)
D. Decreased glutamate synthesis and enhanced glycine-mediated inhibition
E. Direct antagonism of NMDA receptors reducing excitatory neurotransmission

Explanation: ***Metabolic shift producing ketone bodies that stabilize neuronal membranes and alter neurotransmitter levels*** - The ketogenic diet creates a state of **ketosis**, where **ketone bodies** like beta-hydroxybutyrate become the primary fuel source, leading to **hyperpolarization** and stabilization of neurons. - It enhances **mitochondrial biogenesis** and modulates the balance of **inhibitory and excitatory neurotransmitters**, which raises the seizure threshold. *Reduction in neuronal excitability through GABA receptor upregulation* - While the diet may increase **GABA synthesis** and reduce its degradation, it does not primarily work through simple **receptor upregulation**. - This mechanism is more characteristic of pharmacological agents like **benzodiazepines** or barbiturates rather than a dietary metabolic shift. *Inhibition of voltage-gated sodium channels in neuronal membranes* - This is the primary mechanism of action for many **anti-epileptic drugs (AEDs)** such as **phenytoin** and carbamazepine. - Although the ketogenic diet has broad effects on excitability, it does not exert its main clinical effect via the direct inhibition of these specific **ion channels**. *Decreased glutamate synthesis and enhanced glycine-mediated inhibition* - While the diet does decrease **glutamate** (an excitatory neurotransmitter), the role of **glycine** is not a fundamental or primary pathway for its anti-seizure effects. - The diet is better known for its effect on the **glutamate-glutamine cycle** rather than specific glycine-mediated inhibition. *Direct antagonism of NMDA receptors reducing excitatory neurotransmission* - Direct **NMDA receptor antagonism** is a mechanism associated with drugs like **ketamine** or felbamate. - The ketogenic diet reduces the availability of excitatory substrates but is not classified as a direct **pharmacological antagonist** of the NMDA receptor.

Question 10: A 9-year-old boy with type 1 diabetes for 4 years uses a basal-bolus insulin regimen. His parents report that his morning pre-breakfast blood glucose readings are consistently high (12-15 mmol/L), despite having good control during the day. His bedtime readings are usually 6-8 mmol/L. A continuous glucose monitor shows that his glucose drops to 3.2 mmol/L at 2am then rises sharply to 14 mmol/L by 7am. What is the most appropriate adjustment to his insulin regimen?

A. Increase the evening long-acting insulin dose
B. Decrease the evening long-acting insulin dose (Correct Answer)
C. Add a bedtime snack containing complex carbohydrates
D. Increase the lunchtime rapid-acting insulin dose
E. Split the long-acting insulin to twice daily dosing

Explanation: ***Decrease the evening long-acting insulin dose***- The patient exhibits the **Somogyi phenomenon**, where **nocturnal hypoglycemia** (3.2 mmol/L at 2am) triggers a counter-regulatory hormone surge, causing **rebound hyperglycemia** by morning.- Reducing the evening **basal insulin** prevents the initial drop in glucose, thereby eliminating the subsequent hormonal spike and morning hyperglycemia.*Increase the evening long-acting insulin dose*- Increasing the dose would worsen the **nocturnal hypoglycemia** and potentially increase the severity of the rebound effect.- This intervention is appropriate for the **Dawn Phenomenon**, which lacks the dip into hypoglycemia seen here.*Add a bedtime snack containing complex carbohydrates*- While a snack might mitigate the 2am drop, it does not directly address the underlying issue of **excessive basal insulin** delivery.- Adjusting the **insulin dose** is the primary management strategy for confirmed Somogyi effects on a glucose monitor.*Increase the lunchtime rapid-acting insulin dose*- Changes to **bolus insulin** at lunch affect post-prandial readings during the afternoon and evening.- It has no clinical impact on the **overnight glucose profile** or the morning hyperglycemia observed in this case.*Split the long-acting insulin to twice daily dosing*- Splitting the dose can help with **insulin coverage gaps** but doesn't solve the issue of a too-high total relative concentration at night.- The immediate priority is **dose reduction** to ensure safety and prevent symptomatic or asymptomatic nighttime hypoglycemia.

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free